Gamida Cell Provides Update on Operations in Israel Following Recent Attacks
Gamida Cell, a leading cell therapy company, has issued an update on its operations in Israel following the recent attacks in the country. The company expresses its deepest condolences to the people of Israel and stands in solidarity with its employees and the State of Israel during this difficult time.
Abbey Jenkins, President and CEO of Gamida Cell, stated, “We remain profoundly saddened by the attacks in Israel this weekend and express our deepest condolences to the people of Israel as they mourn the loss of loved ones and defend themselves.” Jenkins further confirmed that all Gamida Cell employees in Israel are safe, and the company’s manufacturing facility is operational.
Gamida Cell had previously issued a statement on October 7 condemning the attacks on Israel and reiterating its support for its employees and the State of Israel.
The company is committed to serving its customers and patients, and it appreciates the support received from its partners and investors. Gamida Cell will continue to closely monitor the situation and provide updates as necessary.
Gamida Cell is a pioneer in the field of cell therapy, working to transform cells into powerful therapeutics. The company’s proprietary nicotinamide (NAM) technology enhances and expands cells, creating potentially curative allogeneic cell therapy products for patients with hematologic malignancies. Gamida Cell’s portfolio includes Omisirge™ (omidubicel-onlv), an FDA-approved nicotinamide modified allogeneic hematopoietic progenitor cell therapy, and GDA-201, an intrinsic NK cell therapy candidate being investigated for the treatment of hematologic malignancies.
For more information about Gamida Cell and its innovative cell therapy solutions, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, X, Facebook, or Instagram.
Cautionary Note Regarding Forward-Looking Statements:
This statement contains forward-looking statements regarding Gamida Cell’s ability to maintain its operations in Israel and the potential impact of future developments. These statements are subject to various risks and uncertainties, including clinical, scientific, regulatory, and technical factors. Actual results may differ materially and adversely from those anticipated or implied by these forward-looking statements. It is advised not to rely solely on these statements and to refer to Gamida Cell’s filings with the Securities and Exchange Commission for a comprehensive understanding of the risks involved.
Source: [Business Wire](https://www.businesswire.com/news/home/20231009890654/en/)